Sinorda Biomedicine

Executive Summary

Sinorda Biomedicine is a preclinical-stage biotechnology company based in Suzhou, China, focused on developing novel antibody-based therapeutics for oncology and autoimmune diseases. Founded in 2016, the company leverages advanced antibody engineering to create bispecific and multi-specific formats aimed at improving efficacy and safety profiles. Sinorda operates in a competitive landscape but differentiates with its proprietary platform. As a private company with no disclosed funding or valuation, its progress depends on advancing its pipeline toward IND-enabling studies. The company’s early-stage status implies high risk but also potential for upside if key milestones are achieved. Its focus on next-generation biologics positions it within growing markets for immuno-oncology and autoimmune therapies.

Upcoming Catalysts (preview)

• Q2 2026IND filing for lead bispecific candidate40% success
• Q3 2026Preclinical proof-of-concept data release60% success
• Q4 2026Partnership or licensing deal for multi-specific platform30% success